Denmark
Antag Therapeutics, founded in 2017, is a pioneering biotechnology company headquartered in Denmark. The company is focused on redefining obesity treatment and empowering patients through its innovative approach of GIP receptor antagonism. This methodology aims to deliver personal and flexible treatment options in the realm of obesity, diabetes, and metabolic dysfunction.
At the heart of Antag’s innovation is its lead molecule, AT-7687, engineered to target and deactivate the GIP receptor, distinct from existing GLP-1 therapies. This approach is backed by the research of the company’s co-founders, Professors Jens Juul Holst and Mette Rosenkilde.
In its last venture round investment on 03 June 2020, Antag Therapeutics secured kr24.00M from eminent investors such as Novo Holdings, Broadview Ventures, Viva BioInnovator, and Vaekstfonden. With a compelling vision centered on long-term health improvements, Antag Therapeutics stands poised for significant impact within the Health and Wellness sector.
